ChatGPT

Perplexity

Gemini

Claude

Grok

Explore the latest styles in fashion, home and beauty with the H&M app. Discover inspiring collections and intuitive features that simplify the shopping experience — from instant search to real-time o

Your top app for online fashion shopping in Saudi Arabia, United Arab Emirates, Kuwait, Egypt, and Qatar.  Download the H&M app and shop all fashion clothing and accessories such as:

- Women's clothe

Erling Persson (1947 Sweden, retail entrepreneur)

Germany fines H&M 35 million euros for data protection breaches

H & M Hennes & Mauritz AB, commonly known by its brand name H&M, is a Swedish multinational clothing company headquartered in Stockholm. Built on a fast fashion business model, the retailer sells apparel, accessories, and homeware. The company operates thousands of stores across 75 geographical markets and employs over 171,000 people worldwide. H&M is the second-largest international clothing retailer after Inditex. H&M was founded by Erling Persson in 1947 under the name Hennes. The CEO of H&M from 2020 to 2024 was Helena Helmersson. The current CEO, as of January 2024, is Daniel Ervér.

Swedish multinational clothing-retail company

H&M generated $22B revenue 2024 as 2nd-largest fashion retailer (Swedish privately-held Persson family, 4,000+ stores 75 countries down from 5,000 peak, fast-fashion $10-40 T-shirts/dresses/basics, Conscious Collection sustainability 50% recycled). Founded 1947 Sweden as Hennes ('Hers') by Erling Persson (women's clothing, 1968 acquired Mauritz Widforss menswear rebranded H&M). 1970s-2000s global (U.S. 2000 NYC, 3,000+ stores, designer collaborations Karl Lagerfeld 2004 $100M sellout). However, 2015-2024 struggles: inventory crisis $4B unsold 2018 (slow fashion cycles versus Zara 2-week, store closures 500+, online 30% transition late), sustainability backlash greenwashing allegations Conscious Collection 5% actually recycled, Shein $30B ultra-fast $5-15 Gen Z. Competing Zara $30B #1 Inditex, Uniqlo $20B basics, Shein $30B online-only $5. Technology: mobile app, membership loyalty, digital receipts, inventory AI predictive limited. Employees 100,000+ (from 120K peak, store closures layoffs).

H&M's Sustainability Push and Inventory Crisis Navigate Fast-Fashion Backlash as Zara Competition and Shein $30B Ultra-Fast Threaten Market Share

H&M reaches $22B revenue as 2nd-largest global fashion retailer with 4,000+ stores, fast-fashion $10-40 model, Swedish origins, struggling Zara competition

H&M HENNES & MAURITZ AB

Women's clothing 'Hers'. Affordable fashion U.S.-inspired. 15 stores Sweden expansion.

Hennes & Mauritz. Added men's hunting/outdoor apparel. Stockholm stock. Sweden national chain.

Fifth Avenue flagship. 3,000+ stores. Fast-fashion model 2-4 week cycles. Zara competition began.

Stella McCartney, Balmain, Versace collabs. Prestige affordable $50-100. Marketing hype lines.

Recycled materials 50% claim. Greenwashing allegations 5% actually recycled. Garment collecting stores.

Slow fashion cycles vs Zara 2-week. Online 30% late transition. Shein $30B $5-15 Gen Z ultra-fast threat.

CEO Helena Helmersson sustainability. Persson family billionaires privately-held. 100K employees (from 120K). Online 30%.

Lilly Health™: Your journey, your way

Whether you’re on Zepbound® (tirzepatide) or Mounjaro® (tirzepatide), Lilly Health™ offers personalized information, education, and insights to help you feel sup

Diabetes Self-Management That Works for You

The TempoSmart™ App collects diabetes-related data that has been captured by the Tempo Smart Button™ and a connected Tempo Blood Glucose Monitor (BGM) or D

Operating with honesty, transparency, and ethical conduct in all business practices and relationships with patients, healthcare providers, and stakeholders.

Integrity

Striving for the highest standards in research, development, manufacturing, and delivery of medicines that improve patient outcomes worldwide.

Excellence

Valuing diversity, cultivating an inclusive culture, and treating all employees, patients, and partners with dignity and care.

Respect for People

Leading pharmaceutical breakthroughs from the first mass-produced insulin and polio vaccine to revolutionary GLP-1 therapies and Alzheimer's treatments.

Innovation

Eli Lilly is the world's most valuable pharmaceutical company, pioneering breakthrough medicines for diabetes, obesity, Alzheimer's disease, and other conditions, with a legacy of innovation spanning nearly 150 years.

Eli Lilly pulls millions in Twitter advertising after fake account debacle

Fake account and $8 blue checkmark wipe $20B off Eli Lilly's market cap

Eli Lilly's weight loss drug slashes the risk of diabetes in long-term trial

Eli Lilly stock fell by $20B because of a fake tweet about free insulin

Eli Lilly says its monoclonal antibody cocktail is effective against Covid-19

David A. Ricks

Chair and Chief Executive Officer

Dr. Ruth Gimeno

Chief Scientific and Medical Officer & President, Lilly Research Laboratories

Ilya Yuffa

President, Lilly Immunology; President, Lilly USA; and Chief Customer Officer

Diogo Rau

Chief Information and Digital Officer

Mike Harrington

President, Lilly Diabetes

Maria Louzao

President, Manufacturing Operations

Anne White

President, Lilly Neuroscience

Jacob Van Naarden

President, Loxo@Lilly

A dual GIP/GLP-1 receptor agonist for type 2 diabetes treatment, approved in May 2022. Mounjaro is the world's best-selling medicine and Lilly's flagship diabetes product, representing a major portion of the company's $10.1 billion in tirzepatide sales in Q3 2024 alone.

Mounjaro (tirzepatide)

The same molecule as Mounjaro but marketed for obesity treatment and obstructive sleep apnea. Approved in November 2023 for weight loss and later for OSA, Zepbound has become a blockbuster drug driving Lilly's record revenue growth. Together, tirzepatide products account for 37% of 2024 revenues.

Zepbound (tirzepatide)

A GLP-1 receptor agonist for type 2 diabetes, launched in 2014. Trulicity accounts for 12% of 2024 revenues and has been a cornerstone of Lilly's diabetes portfolio for over a decade.

Trulicity (dulaglutide)

A rapid-acting insulin analog for diabetes management, approved in 1996. Humalog accounts for 5% of 2024 revenues and remains an important treatment option. In 2023, Lilly reduced Humalog's price from $275 to $66 per month.

Humalog (insulin lispro)

The first human insulin produced using recombinant DNA technology, launched in 1982. Humulin revolutionized diabetes care and established Lilly as a biotechnology pioneer.

Humulin (human insulin)

A long-acting basal insulin for type 1 and type 2 diabetes, providing 24-hour glucose control with once-daily dosing.

Basaglar (insulin glargine)

A monoclonal antibody for Alzheimer's disease treatment, approved by the FDA and UK in 2024. Kisunla represents a breakthrough in treating neurodegenerative diseases by targeting amyloid plaques.

Kisunla (donanemab)

An oral estrogen receptor antagonist for ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer in adults who progressed after endocrine therapy, approved in 2024.

Inluriyo (imlunestrant)

An investigational oral GLP-1 medication in Phase 3 trials for both obesity and type 2 diabetes. Phase 3 results showed weight loss of up to 27.3 lbs and efficacy consistent with injectable GLP-1 medicines, with global regulatory submissions planned for 2024-2025.

Orforglipron (in development)

A comprehensive patient assistance program providing free Lilly medications to eligible U.S. residents who meet income and insurance requirements, helping patients access life-saving treatments regardless of ability to pay.

Lilly Cares Patient Assistance Program

Eli Lilly achieved a historic milestone in November 2024, becoming the first healthcare company in the world to reach a $1 trillion market capitalization. The achievement was driven by blockbuster sales of GLP-1 drugs Mounjaro and Zepbound for diabetes and weight loss.

Eli Lilly Becomes First Pharmaceutical Company to Reach $1 Trillion Market Cap

Lilly reported Q4 2024 revenue of $13.53 billion (up 45% from Q4 2023) and full-year revenue of approximately $45 billion (up 32% from 2023). Q4 net income was $4.41 billion with EPS of $4.88. The company issued 2025 guidance projecting revenue of $58.0-61.0 billion.

Lilly Reports Full Q4 2024 Financial Results

Lilly's oral GLP-1 medication orforglipron successfully completed its third Phase 3 trial for obesity treatment, showing weight loss of up to 27.3 lbs. The results triggered global regulatory submissions planned for 2024-2025, potentially offering the first oral GLP-1 alternative to injections.

FDA Approves Lilly's Oral GLP-1 Orforglipron for Regulatory Submission

The FDA and UK approved Kisunla (donanemab), Lilly's monoclonal antibody for treating Alzheimer's disease. The approval represents a major breakthrough in neurodegenerative disease therapy, targeting amyloid plaques to slow cognitive decline in early-stage patients.

FDA Approves Kisunla for Alzheimer's Disease Treatment

Lilly received FDA approval for Zepbound (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity, expanding the drug's indications beyond weight loss.

Zepbound Approved for Obstructive Sleep Apnea Treatment

Eli Lilly announced plans to construct a $5 billion manufacturing facility in Goochland County, Virginia, which will be the company's first dedicated, fully integrated site for producing bioconjugates and monoclonal antibodies, supporting future capacity needs.

Lilly Announces $5 Billion Virginia Manufacturing Facility

Adverum Biotechnologies agreed to sell to Eli Lilly for $3.56 per share (total deal value approximately $261 million), bringing gene therapy capabilities for vision loss treatment to Lilly's portfolio and expanding the company's ophthalmology pipeline.

Lilly Acquires Adverum Biotechnologies for Gene Therapy Pipeline

Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial

Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market

Eli Lilly raises UK price of weight loss drug Mounjaro by up to 170%

Novo Nordisk sinks 13% after weight loss drug fails to match Eli Lilly's in trial

Can anyone comment on Eli Lilly’s culture ?

Eli Lilly - interview query

About Eli Lilly’s Advisor Position…

Is Eli Lilly going to mess this up for us??

Eli Lilly - Associate Director

Eli Lilly Engineering Salary Worth It?

wallstreetbets

biotech

PharmaEire

unitedkingdom

ValueInvesting

gimmecare

indianapolis

ELI LILLY & Co

Colonel Eli Lilly, a Civil War veteran and pharmaceutical chemist, founded Eli Lilly and Company on May 10, 1876, opening a pharmaceutical laboratory on Pearl Street in Indianapolis with a sign reading 'Eli Lilly, Chemist.'

Company Founded

Eli Lilly formally incorporated the firm as Eli Lilly and Company, elected a board of directors, and issued stock to family members and close associates, establishing the corporate structure.

Formal Incorporation

Lilly became one of the first companies to produce insulin, revolutionizing diabetes treatment and saving countless lives worldwide.

Insulin Production Begins

Lilly became the first company to mass-produce the polio vaccine developed by Jonas Salk, playing a crucial role in eradicating polio globally.

Polio Vaccine Mass Production

Lilly launched Humulin, the first human insulin produced using recombinant DNA technology, marking a breakthrough in biotechnology and diabetes care.

Humulin Launch - First Recombinant DNA Drug

The FDA approved Humalog (insulin lispro), a rapid-acting insulin analog that improved diabetes management for millions of patients.

Humalog Insulin Approval

Exenatide, the first GLP-1 receptor agonist, was approved by the FDA in April 2005, laying the foundation for Lilly's future GLP-1 franchise.

First GLP-1 Drug Approved

Lilly launched Trulicity (dulaglutide), a GLP-1 receptor agonist for type 2 diabetes that became a blockbuster drug generating billions in annual revenue.

Trulicity Launch

David A. Ricks became CEO in January 2017 and was elected Chair in June 2017, leading the company to record growth and the development of transformative medicines.

David Ricks Becomes CEO

The FDA approved tirzepatide under the brand name Mounjaro for type 2 diabetes treatment, launching what would become the world's best-selling medicine.

Mounjaro FDA Approval

Lilly announced a $35 cap on monthly insulin prices and reduced Humalog price from $275 to $66 per month, dramatically improving patient access to life-saving insulin.

$35 Insulin Price Cap

The FDA approved tirzepatide under the brand name Zepbound for obesity treatment in November 2023, expanding the drug's market to weight loss.

Zepbound FDA Approval

The FDA and UK approved Kisunla (donanemab), a monoclonal antibody for Alzheimer's disease treatment, representing a major breakthrough in neurodegenerative disease therapy.

Kisunla FDA Approval

Lilly received FDA approval for Zepbound as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity.

Zepbound OSA Indication Approved

The FDA approved Inluriyo (imlunestrant), an oral estrogen receptor antagonist for treating adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer.

Inluriyo Breast Cancer Approval

Lilly acquired Morphic Holding Inc., expanding its pipeline with novel integrin therapeutics for inflammatory diseases.

Morphic Holding Acquisition

Adverum Biotechnologies agreed to sell to Lilly for $3.56 per share (total deal value ~$261 million), bringing gene therapy capabilities for vision loss treatment.

Adverum Biotechnologies Acquisition

Lilly announced plans to construct a $5 billion manufacturing facility in Goochland County, Virginia, the company's first fully integrated site for bioconjugates and monoclonal antibodies.

$5 Billion Virginia Manufacturing Facility

In November 2024, Eli Lilly reached a $1 trillion market capitalization, becoming the first healthcare company in the world to achieve this milestone, driven by GLP-1 drug success.

First $1 Trillion Pharmaceutical Company

Lilly's oral GLP-1 medication orforglipron demonstrated successful Phase 3 trial results for both obesity and diabetes, with weight loss up to 27.3 lbs, triggering global regulatory submissions.

H&M (Hennes & Mauritz) vs Eli Lilly

H&M (Hennes & Mauritz)

About

Eli Lilly

About

AI Visibility Head-to-Head

Also Compare

Track AI Visibility in Real Time